Tricuspid Regurgitation, Right Heart, and TAVR affects survival in patients with non-AS heart failure. 5, 6 However, the effect of right heart size and function has not been evaluated in patients undergoing TAVR. Accordingly, we evaluated the effect of significant TR and right heart enlargement and dysfunction on mortality in the inoperable cohort of the Placement of Aortic Transcatheter Valves (PARTNER) II trial.
Methods

Study Population
The design, inclusion and exclusion criteria, and primary results of the inoperable cohort (cohort B) of the PARTNER II randomized clinical trial have been reported. 7 The trial was designed to compare the safety and effectiveness of the new lower-profile Edwards Sapien XT transcatheter heart valve to the Sapien valve (approved by the US Food and Drug Administration). The complete inclusion and exclusion criteria are provided in the Data Supplement. These patients had severe AS with an aortic valve area <0.8 cm 2 (or indexed aortic valve area <0.5 cm 2 /m 2 ) and either resting or inducible mean gradient >40 mm Hg or peak jet velocity >4 m/s. They were symptomatic from AS (New York Heart Association functional class ≥2) and had prohibitive surgical risk as defined by a risk of death or serious irreversible morbidity exceeding 50% by 30 days after conventional aortic valve surgery as assessed by the heart team. Patients were eligible for the trial if they had suitable transfemoral access and, once enrolled, were randomized to therapy with the Edwards Sapien or Sapien XT transcatheter heart valve. For this analysis, we included only patients who received treatment with TAVR (the as treated population). Among these patients, 99.3% (538/542) completed 1-year follow-up in the trial. Clinical characteristics were reported by the enrolling sites. Frailty was determined by an integrated evaluation of hand grip strength, 5-m walking speed, serum albumin level, and an assessment of independence in performing activities of daily living. 8, 9 The study protocol was approved by the institutional review board at each enrolling site and all patients provided written informed consent.
Echocardiography and Hemodynamics
An independent core laboratory analyzed all echocardiograms. The severity of AS was determined by measuring mean and peak gradients across the valve using the modified Bernoulli equation and by calculating aortic valve area using the continuity equation.
Measurements of left ventricular (LV) chamber dimensions, ejection fraction, LV mass, and left atrial volume were made as recommended by the American Society of Echocardiography. 10, 11 Stroke volume was calculated as the LV outflow tract area multiplied by the pulsed wave Doppler LV outflow tract velocity-time integral. The severity of aortic regurgitation and MR was determined by an integrative method that includes quantitative and qualitative criteria. 12 TR severity was determined by an integrative, semiquantitative approach as recommended by the American Society of Echocardiography, including assessment of tricuspid valve morphology, right atrial (RA) and RV size, inferior vena cava size, jet area, vena contracta width, proximal isovelocity surface area radius, jet density and contour, and hepatic vein flow. 12 RA area was measured in the 4 chamber view. 13 When images were adequate, RV size was determined by measuring the basal and mid-RV diameter and base-to-apex length in the 4 chamber view and categorized as normal or mildly, moderately, or severely dilated according to the American Society of Echocardiography guidelines. 10, 13 The 3 measurements were used to determine the appropriate category, usually characterized by 2 of the 3 measurements falling in a particular category. RV function was determined by measuring systolic and diastolic area and RV fractional area change when feasible (or by visual estimate) and categorized as normal or mild, moderate, or severe dysfunction according to the American Society of Echocardiography criteria. 10, 13 TR jet velocity and estimated RV systolic pressure were measured as recommended. 13 Per protocol, echocardiograms were obtained at baseline (within 45 days of TAVR), and post-TAVR at discharge (or 7 days), 30 days, and 1 year. The baseline (preprocedure) echocardiogram was used in all of our survival analyses. A pulmonary artery catheter was routinely used during the TAVR cases to obtain invasive hemodynamic measurements before balloon aortic valvuloplasty and after transcatheter valve placement. The measurements reported are those obtained before balloon aortic valvuloplasty.
Statistical Analysis
Continuous variables were summarized as mean±SD and evaluated using an overall F test from an ANOVA. Categorical variables were compared with the χ 2 or Fisher exact test as appropriate. The primary end point for this analysis was all-cause death ≤1 year. Time-toevent curves for 1-year survival, based on all available follow-up data, were performed with the use of Kaplan-Meier estimates and were compared between groups with the use of the log-rank test. Cox proportional hazards models were used to calculate hazard ratios and to test for interactions between TR severity (moderate/severe versus none/trace/mild) and age, sex, renal function, LV ejection fraction, MR severity, RV size, RV function, RA size, and pulmonary artery pressure). Multivariable Cox proportional hazards models adjusted for baseline characteristics with a univariable association (P<0.10) with 1-year mortality including age, sex, body mass index, Society of Thoracic Surgeons score, prior myocardial infarction, prior coronary artery bypass grafting surgery, frailty, permanent pacemaker, atrial arrhythmia, aortic valve mean gradient, LV ejection fraction, and MR. These multivariable analyses evaluated the adjusted relationship between TR severity, RA and RV size, and RV function (each individually) and mortality. They also evaluated the adjusted relationship between TR severity paired with RA size, RV size, or RV function and mortality. To evaluate change in TR severity over time in those with moderate or severe TR at baseline, we reported the number of patients with no/trace/mild, moderate, and severe TR at 30 days and 1 year among patients who survived 1 year with echocardiograms available for analysis at baseline, 30 days, and 1 year. We reported
WHAT IS KNOWN
• Tricuspid regurgitation and right ventricular dysfunction adversely affect outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in patients with aortic stenosis treated with transcatheter aortic valve replacement has not been well characterized.
WHAT THE STUDY ADDS
• In inoperable patients treated with transcatheter aortic valve replacement, moderate or severe tricuspid regurgitation (present in 27% of patients) and right heart enlargement were associated with increased 1-year mortality; however, the association between tricuspid regurgitation and death was only found in patients with minimal mitral regurgitation at baseline.
• Severe tricuspid regurgitation was associated with a 3-fold higher adjusted risk of mortality at 1-year.
• Right ventricular dysfunction was associated with higher mortality after transcatheter aortic valve replacement in univariable analysis, but this association was no longer significant after multivariable adjustment. Data shown as % or mean±SD. AR indicates aortic regurgitation; AVA, aortic valve area; LV, left ventricular; LVEDP, LV end-diastolic pressure; LVMi, LV mass index; mPAP, mean pulmonary artery pressure; MR, mitral regurgitation; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RA, right atrial; RV, right ventricular; STS, Society of Thoracic Surgeons; and TR, tricuspid regurgitation.
*n is the number of subjects with information reported on the particular variable from among the 507 patients with severity of tricuspid regurgitation reported on the baseline echocardiogram. Tricuspid Regurgitation, Right Heart, and TAVR similar data among those with no/trace/mild TR at baseline. To explore the relationship between an improvement in preprocedure moderate or severe TR and clinical outcomes, we compared 30-day to 1-year mortality in patients who improved from moderate to severe TR at baseline to no/trace/mild TR at 30 days versus those who continued to have moderate or severe TR at 30 days. All statistical analyses were performed with SAS software, version 9.2.
Results
Patient Population
Among the 553 patients enrolled in the PARTNER II trial cohort B, 542 were treated with TAVR (Sapien [n=263]; Sapien XT [n=279]). The clinical and echocardiographic characteristics of patients according to the severity of TR are shown in Table 1 . Patients with worse TR were older, had a lower body mass index, higher Society of Thoracic Surgeons score, and greater prevalence of atrial arrhythmia and frailty, but there were no differences in sex, severe heart failure symptoms, coronary disease, or lung disease. Patients with more significant TR had a lower LV ejection fraction and stroke volume index, larger left atrial size, and greater prevalence of moderate/severe MR. Worse TR was also associated with a larger RA and RV, worse RV function, and higher RV systolic pressures.
Mortality Based on TR Severity and the Right Heart
Patients with more significant TR before TAVR had increased 1-year mortality: 32.6% for moderate TR and 61.1% for severe TR compared with 16.9% and 17.2% for those with no/trace or mild TR, respectively (P<0.001; Figure 1A ). Increasing severity of RV dysfunction was also associated with mortality (P<0.001) as were RA and RV enlargement (P<0.001; Figure 1B-1D The event rates were calculated with the use of Kaplan-Meier methods and compared with the use of the log-rank test. CI indicates confidence interval; and HR, hazard ratio. Tricuspid Regurgitation, Right Heart, and TAVR mortality after adjustment, including a >2-fold increase in the hazard of death for moderate or severe RV dilation (HR, 2.20; 95% CI, 1.24-3.90; P=0.007). After multivariable adjustment, the association between RV dysfunction and increased mortality was no longer significant (Table 2 ). Because they did not have a univariable association with mortality and because they were missing in 17% (tricuspid valve regurgitation velocity) and 27% (estimated RV systolic pressure) of subjects with TR severity assessed because of inadequate images of the TR jet or inferior vena cava, we did not include an estimate of pulmonary pressures in our primary multivariable models. To further evaluate the association between TR severity and mortality, we forced various measurements of pulmonary artery pressures (echocardiographic and invasive hemodynamics) into the TR models from Table 2 (Table I in the Data Supplement). The association between moderate/severe TR and an increased hazard of mortality after TAVR was similar to our primary findings. In addition, we adjusted for the severity of paravalvular aortic regurgitation and indices of pulmonary artery pressures on the discharge echocardiogram (Table I in the Data Supplement). Although the association between moderate/ severe TR and increased mortality was modestly attenuated in these models, the point estimates are similar and these models included substantially fewer patients and deaths than the primary models.
When TR was combined with each of these right heart parameters in multivariable analyses, moderate/severe TR generally remained significantly associated with increased mortality. The relationship between RV dilation and mortality was of borderline significance after adjustment for TR severity (P=0.058), whereas RV dysfunction and RA enlargement were not associated with mortality after adjustment for TR severity (Table 3) . When moderate/severe TR occurred with any degree of RV dilation or an increased RA size, those patients had an adjusted hazard of death >2 compared with patients with no/mild TR and a normal RV size or smaller RA size (Table 3) .
Among patients with moderate/severe TR at baseline and a 30-day assessment of TR severity (n=111), those with improvement to no/trace/mild TR at 30 days (n=34) had a lower rate of death between 30 days and 1 year (20.6%) than those (n=77) with persistent moderate/severe TR (30%), although patient numbers and events were limited and this was not statistically significant (P=0.30). Regardless of baseline TR severity, moderate/severe TR compared with no/trace/ mild TR at 30 days was associated with an increased hazard of 30-day to 1-year mortality (unadjusted HR, 2.39; 95% CI, 1.54-3.73) and there was no interaction between 30-day TR severity and pulmonary pressures with respect to 30-day to 1-year mortality ( Figure I in the Data Supplement).
TR and MR
We evaluated whether the association between moderate/ severe TR and increased mortality was consistent across several subgroups (Figure 2 ). There was a significant interaction between TR and MR severity (interaction P=0.04). In patients with no/trace/mild MR, the presence of moderate/ severe TR was associated with an increased unadjusted 1-year mortality (unadjusted HR, 3.02; 95% CI, 1.83-4.99), whereas it was not in those with concomitant moderate/severe MR (unadjusted HR, 1.38; 95% CI, 0.77-2.46; Figure 2 ). Patients with moderate/severe TR and no/trace/mild MR had a 1-year mortality of 36.5% compared with 14.6% in patients with no/ trace/mild TR and MR (Figure 3 ), which in adjusted analyses was associated with an increased hazard of death in the first year after TAVR (adjusted HR, 2.55; 95% CI, 1.50-4.32; P<0.001; Table 4 ). Among patients with moderate/severe MR, moderate/severe TR was not associated with an increased hazard of death compared with no/trace/mild TR in adjusted analyses (adjusted HR, 1.08; 95% CI, 0.58-1.98).
Change in TR and RV Function After TAVR
Among 1-year survivors with moderate or severe TR at baseline, approximately one-third had improvement to no/ trace/mild TR at 30-day and 1-year follow-up ( Figure 4A ). In contrast, among 1-year survivors with no/trace/mild TR at baseline, a smaller percentage had progression to moderate or severe TR at 30-day and 1-year follow-up ( Figure 4B ). Comparable data are shown for RV function over time in Figure 4C and 4D.
Discussion
In patients with prohibitive surgical risk treated with TAVR in the PARTNER II trial, we found that moderate or severe TR and right heart enlargement and dysfunction are associated with increased mortality during the first year after the procedure. Severe TR was associated with a 3-fold increase in the hazard of 1-year mortality after multivariable adjustment. Similarly, after adjustment, larger RA size and RV dilation were associated with increased mortality, whereas RV dysfunction was not. Interestingly, the relationship between moderate/severe TR and increased 1-year mortality differed based on the severity of MR at baseline in that moderate/ severe TR was associated with a 3-fold higher hazard of death in those with minimal MR, but was not associated with increased mortality in those with concomitant moderate or severe MR. Collectively, these findings demonstrate the importance of right-sided pathology in outcomes for patients undergoing TAVR and may have implications for treatment decisions, including assessment of anticipated benefit from TAVR and whether concomitant surgical treatment of TR should be considered in selected operable patients. Recently, Barbanti et al 4 reported that although moderate/ severe TR was associated with worse survival in patients undergoing TAVR, this association was no longer significant after multivariable adjustment. When comparing their study to the present one, there are some notable differences. They looked at all patients treated with TAVR via femoral and alternative access routes at a single center, whereas we evaluated patients treated only via a transfemoral approach within the context of a multicenter trial who were considered inoperable. In the Barbanti study compared with the PARTNER II inoperable cohort, there were differences in the prevalence of moderate/ severe TR (15.2% versus 26.6%, respectively) and moderate/ severe MR (40.1% versus 29.1%, respectively), which could have influenced the findings. Just as there have been conflicting results on the effect of significant MR on outcomes after TAVR, [1] [2] [3] perhaps the effect of significant TR differs based on a variety of factors that remain to be elucidated. Our results, however, are consistent with studies in patients undergoing mitral valve surgery and an unselected population of patients undergoing an echocardiogram demonstrating the adverse effect of significant TR on mortality. [14] [15] [16] Beyond providing another evaluation of the effect of significant TR on outcomes after TAVR, we extend the findings of Barbanti et al by providing new insights on the effects of right heart dilation and dysfunction.
We did not observe an association between pulmonary hypertension and mortality, whereas several other studies have demonstrated an association between increased pulmonary pressures and increased mortality after AVR. [17] [18] [19] [20] [21] However, in some of these studies the association between pulmonary hypertension and increased mortality was modest. For example, Lucon et al 22 recently reported that in the large French Aortic National CoreValve and Edwards (FRANCE 2) registry, mild to moderate pulmonary hypertension was not associated with 1-year mortality. Although severe pulmonary hypertension was associated with increased mortality, this association was modest (HR, 1.33; 95% CI, 1.01-1.75). The median pulmonary artery systolic pressure was minimally different between survivors and nonsurvivors (45 versus 43 mm Hg). Other studies in this patient population have not identified pulmonary hypertension as a risk factor for mortality. 4 As such, we believe our finding that pulmonary pressures are not associated with 1-year mortality in the PARTNER 2B study is not an anomaly. We think this lack of an association between estimates of pulmonary artery Multivariable Cox proportional hazards models evaluating the association between TR severity (moderate/severe vs no/trace/mild) combined with right heart size and function and 1-year all-cause death. All results are adjusted for age, sex, body mass index, Society of Thoracic Surgeons score, prior infarct, prior coronary artery bypass grafting surgery, frailty, permanent pacemaker, atrial arrhythmia, aortic valve mean gradient, left ventricular ejection fraction, and mitral regurgitation. For each set of variables (RV function+TR, RV size+TR, and RA area index+TR), there are 2 models shows. In each case, model 1 includes TR severity and the right heart variable (RV function, RV size, or RA area index) as individual variables in the model, adjusted for the variables listed above. Model 2 combines TR severity and the right heart variable to create 4 groups as described, adjusted for the same variables. CI indicates confidence interval; RA, right atrial; RV, right ventricular; and TR, tricuspid regurgitation.
*RA area index optimal cut point: 9.16 cm pressure and mortality in this cohort may be explained by several factors. First, the relationship between pulmonary artery pressure and mortality may not be linear and may be more clearly observed when grouping patients based on the severity of pulmonary hypertension. Second, perhaps in this relatively sicker and inoperable cohort of patients, the relationship between pulmonary hypertension and mortality is diluted by the numerous comorbidities and other factors that are driving mortality. Third, as RV function begins to worsen (RV dysfunction was present in 32% of this cohort), the pulmonary pressures may begin to drop as disease progression advances. This would confound a clear association between higher pulmonary pressures and increased mortality.
Right Heart and Outcomes After TAVR
Several studies have demonstrated the independent and additive adverse effect of RV dysfunction on clinical outcomes in patients with left-sided heart failure. 5, 6, 23 Small studies have evaluated the effect on perioperative outcomes of RV dysfunction in patients with mitral or aortic valve disease, 24 but the effect of RV dysfunction on longer term outcomes after valve replacement, particularly TAVR, has not been studied. RV function may be abnormal in patients with AS because of (1) pressure overload from increased left-sided filling pressures and pulmonary artery pressures transmitted to the right side; (2) volume overload from fluid retention or concomitant TR; (3) myocardial ischemia from coronary disease; or (4) ventricular interdependence because of septal dysfunction. We found that although increasing severity of RV dysfunction was associated with worse clinical outcomes, this relationship was no longer significant after multivariable adjustment. However, more quantitative or sensitive measures of RV function than those obtained in this study may identify a stronger association. In contrast, we found that RV dilation was independently associated with mortality in patients treated with TAVR, which is analogous to and consistent with several studies that have identified LV remodeling/size as a better predictor of outcomes than LV function (eg, ejection fraction) in patients with left-sided heart failure. 25, 26 Perhaps RV size better reflects the chronicity and severity of pressure or volume overload on the RV than ventricular function. Although most studies evaluating the RV in patients with leftsided heart failure have examined the prognostic significance of RV dysfunction, others have demonstrated an independent association between RV enlargement and mortality in patients with dilated cardiomyopathy.
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TR and MR
We found that the increased hazard of moderate/severe TR in patients treated with TAVR differed based on the severity of concomitant MR. Why might moderate/severe TR increase the hazard of death in those with no/trace/mild MR, but not in those with moderate/severe MR? It is noteworthy that patients with no/trace/mild TR and MR had a low 1-year mortality at 14.6%, demonstrating an excellent outcome for patients with isolated AS treated with TAVR. Compared with Figure 2 . Effect of clinical and echocardiographic factors on the association between tricuspid regurgitation (TR) severity and 1-year death from any cause. Cox proportional hazards models were used to evaluate the hazard ratios for 1-year death from any cause for patients with moderate/severe vs no/trace/mild TR in the clinical and echocardiographic subgroups shown. CI indicates confidence interval; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; and PA, pulmonary artery. Tricuspid Regurgitation, Right Heart, and TAVR this group of patients, those with moderate/severe TR had an adjusted hazard of death 2.5-fold higher. Among patients with moderate/severe MR, those with concomitant moderate/ severe TR had a higher 1-year mortality compared with those with no/trace/mild TR (36.2% versus 27.5%, respectively), but the increased hazard of death associated with moderate/ severe TR was not significant among these patients in unadjusted or adjusted analyses. To the extent that moderate/ severe TR is influenced by the presence of moderate/severe MR (perhaps because of increased pulmonary venous and arterial pressures from significant MR exacerbating pressure overload and dilation of the RV), the MR may get somewhat better after TAVR, thereby reducing pressure overload on the RV and facilitating improvement in TR. In contrast, if moderate/severe TR is not influenced by the presence of MR (because it is absent or minimal), then TAVR will not lead to any reduction of MR that might help reduce concomitant TR. Further studies are needed to clarify this relationship and its clinical implications; our data would suggest that it may be all the more important to consider a concomitant tricuspid valve procedure in those patients with minimal MR.
Clinical Implications
At a time when the utilization of TAVR is rapidly expanding and extending into lower risk patients, the issue of concomitant mitral and tricuspid valve regurgitation, their effect on clinical outcomes, and how to best treat the patient with multiple valve lesions will require further investigation and careful discussions in the context of a heart valve team. Our findings demonstrate that significant TR portends a worse prognosis after TAVR in extreme risk patients and suggest that it should be considered in a comparable light with concomitant significant MR when making treatment decisions in patients considered for TAVR. Although the patients in the current study were considered prohibitive risk for surgery such that a concomitant tricuspid valve procedure was not really a viable option, our findings raise important questions about how significant TR (and perhaps tricuspid annular dilation) ought to factor into treatment decisions (TAVR versus surgical valve replacement) for patients with more modest surgical risk. It may be that in some patients, the addition of a tricuspid repair to surgical aortic valve replacement may lead to better outcomes than TAVR accompanied by no treatment of TR or later surgical repair. Treatment guidelines for intermediate and high-risk patients with severe AS and concomitant significant TR or MR will require additional studies aimed at clarifying these issues. Beyond the question of whether and when concomitant TR should be corrected, our findings show that in patients at prohibitive surgical risk, the presence of severe TR portends a poor prognosis even if the AS is treated with TAVR, which may shift the risk/benefit ratio toward not performing TAVR.
Limitations
Our findings apply to patients at prohibitive risk for conventional surgery who were treated with TAVR via a transfemoral approach. Further studies are needed to evaluate whether significant TR and right heart dilation and dysfunction adversely affect prognosis after TAVR in patients at intermediate to high risk and those treated via alternative access approaches. Given the small number of patients with severe TR, the hazard of mortality associated with severe TR should be confirmed in future studies. Quantitative measurements of TR severity were not systematically recorded by the core laboratory. The percentage of patients for whom RV function was evaluated by visual estimate versus RV fractional area change is not known. RV function was not evaluated with longitudinal strain or tricuspid annular velocity or displacement, which may have provided a more detailed, quantitative assessment and identified a stronger association between abnormal RV function and mortality. Moreover, because of the complex geometry of the RV, 3-dimensional echocardiography or magnetic resonance imaging may provide additional insights and better One-year time-to-event curves are shown for death from any cause in the as-treated population of the Placement of Aortic Transcatheter Valves II trial inoperable cohort for patients with no/trace/mild TR and no/trace/mild mitral regurgitation (MR; group A), no/trace/mild TR and moderate/severe MR (group B), moderate/severe TR and no/trace/mild MR (group C), and moderate/severe TR and moderate/severe MR (group D). The event rates were calculated with the use of Kaplan-Meier methods and compared with the use of the log-rank test. CI indicates confidence interval; and HR, hazard ratio. Tricuspid Regurgitation, Right Heart, and TAVR characterize the relationship between RV size/structure and outcomes than 2-dimensional echocardiography as used in this study. For the analyses that included pulmonary hypertension, we did not have information to reliably classify the type or group of pulmonary hypertension. There was no adjustment made for multiple comparisons, so borderline significant P values should be interpreted with caution. Finally, although it was likely functional in most cases, we lack a characterization of TR as primary versus secondary/functional.
Conclusions
In the prohibitive risk arm of the PARTNER II trial, moderate or severe TR occurred in 27% of patients and was associated with increased mortality in unadjusted and adjusted analyses, including a 3-fold increase in the adjusted hazard of death among those with severe TR. The increased hazard of death associated with moderate/severe TR was observed in those with no/trace/mild MR, but not in those with concomitant moderate/severe MR. RA and RV dilation were also associated with increased mortality, whereas RV dysfunction was not after multivariable adjustment. Further studies are needed to clarify these relationships and their implications for treatment decisions.
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